Compare Emerson Electric Co. (EMR) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Emerson Electric Co. vs Viatris Inc — how do they compare? Emerson Electric Co. trades at $137.41 (market cap $76.31B), while Viatris Inc trades at $17.2 (market cap $19.44B). The key difference: Emerson Electric Co. is far larger — about 3.9× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.88%). Which is the better fit depends on your goals.
| EMR | VTRS | |
|---|---|---|
Market Cap | $76.31B | $19.44B |
Sector | Industrials | Health |
52-Week High | $161.69 | $17.39 |
52-Week Low | $123.30 | $8.74 |
Enterprise Value | $88.58B | $31.65B |
Dividend Yield | 1.63% | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Emerson Electric (EMR) trades at $137.06, up 0.7% on the day, with a bearish technical signal but strong analyst support. Recent earnings have mostly beaten expectations, with Q2 2026 results pending. The company maintains solid profitability with a 13.35% net income margin and a consensus price target of $157.60, suggesting 15% upside. Cash flow trends show operational strength despite net outflows, and a dividend of $0.56 was recently declared.
EMR presents a mixed outlook: bullish fundamentals and analyst ratings contrast with near-term technical weakness. Investment appeal hinges on earnings execution and sector momentum, while risks include debt levels and market volatility. The stock's valuation at a P/E of 31.54 requires sustained growth to justify further gains.
Viatris (VTRS) trades at $17.215, up 5.55% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3 billion in 2025 but posted a net loss of $3.51 billion, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a decision expected by December 2026. Analyst consensus leans toward Hold, with a $20 price target suggesting modest upside from current levels.
The outlook for VTRS hinges on successful pipeline execution and debt management, offering value potential if biosimilar and specialty drug launches gain traction. Key risks include persistent negative margins, high debt levels, and competitive pressures in the generics market. Investors should weigh the company's cost-cutting efforts and product diversification against its profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
